Healthcare / BiotechnologyNasdaqGS
$2.85
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-53.7M · quality 52.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
6/100
F
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$259M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-87.0%
↓Gross Margin
N/A
•Debt/Equity
0.79
↑Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2009–2025 · 16 años de histórico normalizado
Revenue CAGR
-1.0%
FCF CAGR
—
FCF margin
-33.9%
FCF / Net income
0.54x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $70.4M · net income $-44.0M · FCF $-23.8M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||||||||||
| Revenue | $70.4M | $70.4M | $59.3M | $70.1M | $138.6M | $104.8M | $69.1M | $68.5M | $60.6M | $50.0M | $48.8M | $41.8M | $35.3M | $31.9M | $88.3M | $123.9M | $107.1M | $82.9M |
| Net Income | $-44.0M | $-44.0M | $-65.3M | $-76.2M | $-33.6M | $-21.3M | $-24.0M | $-11.9M | $-10.9M | $-23.0M | $-8.6M | $-7.6M | $-19.1M | $-41.3M | $-30.9M | $-16.6M | $-8.5M | $-20.3M |
| EBITDA | $-36.5M | $-36.5M | $-53.6M | $-62.6M | $-29.5M | — | — | — | — | — | — | — | — | — | — | — | — | — |
| EPS | -0.50 | -0.50 | -0.89 | -1.12 | -0.51 | -0.33 | -0.40 | -0.21 | — | — | — | — | — | — | — | — | — | — |
| Operating Margin | -59.3% | -59.3% | -98.6% | -97.0% | -25.2% | -21.7% | -34.6% | -18.3% | -18.6% | -45.9% | -17.5% | -18.6% | -54.1% | -128.9% | -34.6% | -12.8% | -6.7% | -22.2% |
| Net Margin | -62.5% | -62.5% | -110.0% | -108.7% | -24.2% | -20.3% | -34.8% | -17.4% | -18.0% | -46.0% | -17.5% | -18.1% | -54.0% | -129.4% | -34.9% | -13.4% | -8.0% | -24.5% |
| Balance Sheet | ||||||||||||||||||
| Debt/Equity | 0.79 | 0.79 | 0.43 | 0.00 | — | — | — | — | — | 0.01 | 0.00 | — | — | — | — | — | — | — |
| Cash Flow | ||||||||||||||||||
| Free Cash Flow | $-23.8M | $-23.8M | $-53.7M | $-57.1M | $3.0M | $-28.1M | $-20.2M | $-16.3M | $-16.9M | $-9.7M | $-2.7M | $-1.6M | $19000.00 | $-24.2M | $-14.8M | $-11.2M | $-23.4M | $-19.5M |
| Returns | ||||||||||||||||||
| ROE | -87.0% | -87.0% | -97.5% | -88.0% | -23.2% | -12.9% | -14.1% | -11.3% | -19.3% | -93.7% | -44.8% | -33.1% | -72.5% | -99.6% | -39.3% | -16.1% | -8.0% | 14.0% |
| Growth & Yield | ||||||||||||||||||
| Revenue Growth | 18.6% | 18.6% | -15.4% | -49.4% | 32.3% | 51.7% | 0.9% | 13.0% | 21.1% | 2.4% | 16.8% | 18.4% | 10.6% | -63.8% | -28.7% | 15.6% | 29.2% | — |
| EPS Growth | 43.8% | 43.8% | 20.5% | -119.6% | -54.5% | 17.5% | -90.5% | — | — | — | — | — | — | — | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Unavailable: positive start/end prices are required.